Welcome to our dedicated page for Kalvista Pharm news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on Kalvista Pharm stock.
KalVista Pharmaceuticals develops and commercializes oral small-molecule therapies for rare diseases, with a focus on the kallikrein-kinin system. Its FDA-approved product EKTERLY (sebetralstat) is an oral plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema, and company updates often center on launch activity, product revenue, and use of oral on-demand therapy in HAE.
KalVista news also covers clinical and scientific updates for sebetralstat, including pediatric HAE work through the KONFIDENT-KID trial, medical-conference presentations, financial results, inducement equity grants, governance matters, capital-structure disclosures, and material agreements.
KalVista Pharmaceuticals (NASDAQ: KALV), a clinical stage pharmaceutical company, will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 9:20 a.m. ET.
A live webcast will be available on the company's website, followed by an audio archive accessible for 30 days. KalVista focuses on small molecule protease inhibitors targeting unmet medical needs, including therapies for hereditary angioedema and diabetic macular edema.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced new data on KVD900, its lead oral treatment for hereditary angioedema (HAE), to be presented at the AAAAI Annual Scientific Meeting 2022 from February 25-28 in Phoenix, AZ. Key presentations include:
- Rapid Plasma Kallikrein Inhibition: Early symptom relief in HAE patients by Edward J. Duckworth on February 28.
- Patient Global Impression of Change: Correlation with attack resolution by Paul Audhya on February 28.
KalVista specializes in small molecule protease inhibitors targeting significant unmet medical needs.
KalVista Pharmaceuticals has granted inducement options to purchase 19,000 shares of common stock to four new employees as part of their hiring strategy. The options, issued on February 1, 2022, have an exercise price of $12.72 per share, matching the stock's closing price on the grant date. The vesting schedule allows for one-fourth of the options to vest one year after the grant, followed by monthly vesting over three years. KalVista focuses on developing small molecule protease inhibitors for unmet medical needs, particularly in hereditary angioedema and diabetic macular edema.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has announced the publication of data from its Phase 1 clinical trials for KVD900, an oral on-demand treatment for hereditary angioedema (HAE). The study involved 98 participants and demonstrated near-complete plasma kallikrein inhibition within 30 minutes, indicating KVD900's potential for rapid relief of HAE attacks. The findings were published in the Journal of Allergy and Clinical Immunology, supporting the ongoing development of KVD900 as a promising oral therapy for patients with HAE.
KalVista Pharmaceuticals (NASDAQ: KALV) announced the grant of inducement options for 23,000 shares to four new employees on January 3, 2022. The options have an exercise price of $13.91 per share, matching the closing stock price on the grant date. One-fourth of the options will vest after one year, with the remaining vesting monthly over three years, contingent on continued employment. This issuance follows Nasdaq Listing Rule 5635(c)(4), designed to incentivize new hires as KalVista continues its focus on developing therapies for unmet medical needs.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has provided an operational update alongside its financial results for the second fiscal quarter ended October 31, 2021. The company is initiating a Phase 3 clinical trial for KVD900 and enrolling patients in the KVD824 Phase 2 KOMPLETE trial. Significant progress includes the confirmation of trial designs by the FDA and positive Phase 2 results for KVD900. However, the company reported a net loss of $19.7 million, with no revenue generated during the quarter, and increased R&D and G&A expenses.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the grant of inducement options for 18,000 shares to six newly-hired employees, effective December 1, 2021. The options have an exercise price of $13.63 per share, aligned with the closing stock price on the grant date. Vesting occurs over four years: one-fourth after one year, with remaining shares vesting monthly over three years. This move complies with Nasdaq Listing Rule 5635(c)(4) and is part of KalVista's strategy to attract talent for its innovative therapies targeting hereditary angioedema and diabetic macular edema.
KalVista Pharmaceuticals (NASDAQ: KALV) has completed a positive End-of-Phase 2 meeting with the FDA regarding its clinical trial for KVD900, an oral treatment for hereditary angioedema (HAE). The company expects to initiate its Phase 3 trial in Q1 2022, with positive results from previous trials supporting the trial design. The Phase 3 trial will recruit approximately 100 patients across over 50 sites worldwide, aiming to evaluate symptom relief times, including severe HAE attacks. KalVista is well-capitalized, expected to fund operations until early 2024.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced its participation in two upcoming investor conferences:
- Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 9:20 a.m. EST
- Jefferies London Healthcare Conference on November 16, 2021, at 5:40 p.m. GMT
Live webcasts of the presentations will be available on www.kalvista.com, with archives accessible for 30 days post-event. KalVista focuses on small molecule protease inhibitors for unmet medical needs, including therapies for hereditary angioedema and diabetic macular edema.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) presented Phase 2 data for KVD900 at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting. KVD900 is an oral treatment for hereditary angioedema (HAE) that demonstrated rapid absorption, with significant symptom relief observed faster than placebo (1.6 hours vs 9.0 hours, p0.0001). The findings suggest KVD900 could significantly improve patient outcomes during HAE attacks. The data also indicates strong agreement between Patient Global Impression of Change and other reported outcomes, underscoring its clinical relevance.